- Home
- ALGS vs ACRV Comparison
ALGS vs ACRV Comparison
Compare ALGS & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALGS
- ACRV
- Stock Information
- Founded
- ALGS 2018
- ACRV 2018
- Country
- ALGS United States
- ACRV United States
- Employees
- ALGS N/A
- ACRV N/A
- Industry
- ALGS Biotechnology: Pharmaceutical Preparations
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- ALGS Health Care
- ACRV Health Care
- Exchange
- ALGS Nasdaq
- ACRV Nasdaq
- Market Cap
- ALGS 56.7M
- ACRV 47.8M
- IPO Year
- ALGS 2020
- ACRV 2022
- Fundamental
- Price
- ALGS $9.74
- ACRV $2.30
- Analyst Decision
- ALGS Strong Buy
- ACRV Buy
- Analyst Count
- ALGS 2
- ACRV 5
- Target Price
- ALGS $60.00
- ACRV $14.67
- AVG Volume (30 Days)
- ALGS 90.2K
- ACRV 1.3M
- Earning Date
- ALGS 11-06-2025
- ACRV 11-13-2025
- Dividend Yield
- ALGS N/A
- ACRV N/A
- EPS Growth
- ALGS N/A
- ACRV N/A
- EPS
- ALGS N/A
- ACRV N/A
- Revenue
- ALGS $2,646,000.00
- ACRV N/A
- Revenue This Year
- ALGS N/A
- ACRV N/A
- Revenue Next Year
- ALGS N/A
- ACRV $805.34
- P/E Ratio
- ALGS N/A
- ACRV N/A
- Revenue Growth
- ALGS N/A
- ACRV N/A
- 52 Week Low
- ALGS $3.76
- ACRV $1.05
- 52 Week High
- ALGS $46.80
- ACRV $8.00
- Technical
- Relative Strength Index (RSI)
- ALGS 62.50
- ACRV 56.01
- Support Level
- ALGS $5.81
- ACRV $2.18
- Resistance Level
- ALGS $7.00
- ACRV $2.39
- Average True Range (ATR)
- ALGS 0.79
- ACRV 0.19
- MACD
- ALGS 0.38
- ACRV 0.00
- Stochastic Oscillator
- ALGS 88.61
- ACRV 72.02
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.